Clinical Observation on ShenlingBaizhuPowder Combined with Insulin Degludec/Insulin Aspart in Treating Type 2 Diabetes Mellitus with Spleen Deficiency and Dampness Excess
Objectives To explore the clinical efficacy of ShenlingBaizhu Powder combined with insulin degludec/insulinaspart in the treatment of type 2 diabetes mellituswith spleen deficiency and dampness excess.Methods A total of 60 patients with type 2 diabetes of spleen deficiency and dampness excess type admitted to our hospital from January 2022 to December 2023 were randomly divided into observation group and control group,with 30 cases in each group.The control group was treated with subcutaneous injection of insulin degludec/insulinaspart,and the observation group was treated with modified ShenlingBaizhu Powder combined withinsulin degludec/insulinaspart.The TCM symptom scores,fasting blood glucose,and 2-hour postprandial blood glucose of patients with type 2 diabetes of spleen deficiency and dampness before and after treatment were compared between the two groups,and the glycosylated hemoglobin indexes of the two groups after 2 months of treatment were compared.Results After treatment,the TCM symptom score,fasting blood glucose,2-hour postprandial blood glucose and glycosylated hemoglobin in the observation group were better than those in the control group(P＜0.05).The total effective rate of the observation group was significantly better than that of the control group,and the difference was statistically significant(P＜0.05).Conclusions ShenlingBaizhu Powder combined withinsulin degludec/insulinaspartcan improve the clinical symptoms and blood glucose indicators of type 2 diabetes patients with spleen deficiency and dampness excess,and improve the quality of life of patients.
Addition and subtraction of ShenlingBaizhuPowderInsulin degludec/insulin aspartType 2 diabetes with spleen deficiency and dampness excess
万方数据
维普
